// App-Quantinova.ai

2217 : Pegylated arginine deiminase sensitizes ASS1-negative and KRAS mutant non-small cell lung cancer to PD-1 blockade immunotherapy

Researchers

Presenter

  • Iuliia Pavlyk

Principal Investigators

  • Julie Foster

  • Katie Dexter

  • Jane Sobasowski

  • John Bomalarski

  • Chiara Berlato

  • Frances Balkwill

  • Peter W Szlosarek

Medical Centers

  • Queen Mary University of London, William Harvey Research Institute, London, United Kingdom

  • Polaris Pharmaceuticals Inc, San Diego, CA

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Lung Cancer

  • Melanoma

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

  • Translocator protein

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • Atezolizumab

  • citrulline

  • Pemetrexed

  • ADI-PEG20

  • Arginine hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT03498222

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved